SP1 and prostate carcinoma: Among these, we focused our attention on KLF5 because several putative KLF5‐binding sites are present in the Sp1 promoter region (Fig 3I) and because a KLF5 deletion was already linked to Sp1 upregulation in a model of prostate cancer progression (Xing et al,2014).